Evidence map›Paper›PMID 36767285›Full record

Observational studyInternational journal of environmental research and public health2023

Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study.

Clara Ureña-Paniego, Trinidad Montero-Vílchez, Raquel Sanabria-de-la-Torre, Alberto Soto-Moreno, Alejandro Molina-Leyva, Salvador Arias-Santiago

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Global Prevalence of Sexual Dysfunction in Individuals With Atopic Dermatitis and Asthma: A Systematic Review and Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Clara Ureña-PaniegoDepartment of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.
Trinidad Montero-VílchezDepartment of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.ORCID 0000-0003-4035-7955
Raquel Sanabria-de-la-TorreInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0002-3261-6745
Alberto Soto-MorenoDepartment of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.
Alejandro Molina-LeyvaDepartment of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.ORCID 0000-0001-6882-2113
Salvador Arias-SantiagoDepartment of Dermatology, Virgen de las Nieves University Hospital, 18012 Granada, Spain.ORCID 0000-0002-4186-1435
Instituto de Investigación Biosanitaria de Granada · ESHospital Universitario Virgen de las Nieves · ESUniversidad de Granada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting as xerosis, eczema and intense pruritus. These symptoms negatively impact patients' quality of life. However, the effect of AD on sexual function and sleep quality and how treatment with dupilumab could modify them have not been explored in depth. The aim of this study is to assess the effects of dupilumab on sexual and sleep quality in patients with AD. For that purpose, an observational prospective study was designed. Patients were evaluated at baseline and after 16 weeks of dupilumab treatment. Disease severity was assessed by Eczema Area and Severity (EASI) and SCORing Atopic Dermatitis index (SCORAD). Sexual function was evaluated using validated questionnaires, for men via the International Index of Erectile Dysfunction 5 (IIEF-5) and for women via the Female Sexual Function Index (FSFI). Sleep impairment was recorded through Pittsburgh Sleep Quality Index (PSQI). Thirty-two patients, with a mean age of 30.53 ± 14.48 years old, were included. Regarding sex, 59.8% (20) were female. Most patients had a severe disease reflected in a mean basal EASI of 23.24 ± 6.74 and a SCORAD of 54.07 ± 13.89. Clinical scores improved after dupilumab treatment. At baseline, 47.37% women presented sexual dysfunction and 66.67% men had erectile dysfunction. FSFI improved from 23.51 to 27.93 points (

Indexed as

Dermatitis, AtopicEczemaErectile DysfunctionAdolescentAdultAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeSeverity of Illness IndexSleep QualityTreatment OutcomeAntibodies, Monoclonal, Humanizeddupilumabatopic dermatitisdupilumabsexual healthsleep quality

Identifiers

PMID36767285
PMCPMC9914896
OpenAlexW4317528860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.